Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03115801
What this trial is testing

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Who this might be right for
Metastatic Renal Cell CarcinomaMetastatic Urothelial Carcinoma
Weill Medical College of Cornell University 6
Large-scale testing (Phase 3)Study completedNCT03675737
What this trial is testing

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Who this might be right for
Stomach Neoplasms
Merck Sharp & Dohme LLC 1,579
Testing effectiveness (Phase 2)Study completedNCT02899195
What this trial is testing

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma

Who this might be right for
MesotheliomaPleural Mesothelioma
PrECOG, LLC. 55
Not applicableUnknownNCT04891900
What this trial is testing

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric CancerAdenocarcinoma of Esophagogastric Junction
Henan Cancer Hospital 25
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06229067
What this trial is testing

Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 182
Testing effectiveness (Phase 2)Ended earlyNCT05949632
What this trial is testing

INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Incyte Corporation 5
Testing effectiveness (Phase 2)Ended earlyNCT04066595
What this trial is testing

Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma.

Who this might be right for
Urothelial Carcinoma
Johannes Gutenberg University Mainz 7
Testing effectiveness (Phase 2)Looking for participantsNCT06827236
What this trial is testing

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

Who this might be right for
Locally Advanced Breast CancerUnresectable Breast CarcinomaMetastatic Breast Cancer
BioNTech SE 380
Early research (Phase 1)Study completedNCT01953692
What this trial is testing

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)

Who this might be right for
Myelodysplastic SyndromeMultiple MyelomaHodgkin Lymphoma+4 more
Merck Sharp & Dohme LLC 197
Large-scale testing (Phase 3)Active Not RecruitingNCT06295731
What this trial is testing

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)
Inhibrx Biosciences, Inc 410
Testing effectiveness (Phase 2)Ended earlyNCT03407170
What this trial is testing

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Who this might be right for
Advanced Melanoma
Merck Sharp & Dohme LLC 1
Testing effectiveness (Phase 2)Looking for participantsNCT04165070
What this trial is testing

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Merck Sharp & Dohme LLC 450
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486
Large-scale testing (Phase 3)Study completedNCT04934722
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Merck Sharp & Dohme LLC 186
Not applicableUnknownNCT03917537
What this trial is testing

WGA in Platinum-refractory HNSCC Underwent Nivolumab

Who this might be right for
HNSCC
Chang Gung Memorial Hospital 80
Large-scale testing (Phase 3)Ended earlyNCT06790966
What this trial is testing

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Who this might be right for
Recurrent Head and Neck CancerMetastatic Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell Carcinoma+2 more
PDS Biotechnology Corp. 12
Testing effectiveness (Phase 2)WithdrawnNCT07134556
What this trial is testing

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Who this might be right for
Triple Negative Breast CancerPDL-1 Positive
MedSIR
Not applicableUnknownNCT05701553
What this trial is testing

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma
Shanghai Zhongshan Hospital 20
Large-scale testing (Phase 3)Ended earlyNCT03452137
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Hoffmann-La Roche 406
Testing effectiveness (Phase 2)Study completedNCT04172454
What this trial is testing

Safety and Efficacy of AK104, a PD-1/CTLA-4 Bispecific Antibody, in Selected Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMelanoma
Akeso 68
Next Page